Xin Su | Infectious Diseases | Best Researcher Award

Published on by Infectious

Dr. Xin Su | Infectious Diseases | Best Researcher Award

Attending Physician | Nanjing University | China

Professor Xin Su, M.D., Ph.D., is a distinguished clinical scientist and Chief Physician renowned for his pioneering contributions to respiratory and critical care medicine, with particular expertise in the study and management of severe pulmonary infections. Over a distinguished career spanning nearly three decades, he has demonstrated an exceptional ability to bridge clinical excellence with translational research innovation. His work focuses on the pathogenesis, diagnosis, and treatment of invasive pulmonary aspergillosis (IPA) in non-neutropenic patients, a challenging and underexplored domain of pulmonary medicine. As a leading investigator, Professor Su has spearheaded multicenter studies that have transformed the understanding of pulmonary fungal infections, combining rigorous clinical observation with the use of novel diagnostic technologies, including machine learning and metagenomic sequencing. His publications in high-impact journals such as The Lancet Infectious Diseases, Microbiology Spectrum, Frontiers in Cellular and Infection Microbiology, and Clinical Microbiology and Infection reflect a deep commitment to advancing evidence-based practices and diagnostic accuracy in the field. Through his groundbreaking studies, Professor Su has introduced innovative diagnostic models that integrate big data analytics with clinical biomarkers, offering more precise and timely identification of IPA and related fungal diseases. Beyond diagnostics, his investigations into host immune responses, interferon signaling, and biomarker development have opened new avenues for prognostic assessment and personalized treatment strategies. His leadership roles as a Chief Physician, Professor, and Doctoral Supervisor at Nanjing University-affiliated hospitals underscore his dual impact as both a clinician and academic mentor. Colleagues and collaborators recognize his unique ability to unite global expertise, as evidenced by his participation in international research consortia addressing fungal infections and severe pneumonia outcomes. His scholarly rigor, coupled with his mentorship of young clinicians and researchers, has significantly enriched the field of respiratory and infectious disease research. While Professor Su’s scientific achievements are substantial, he continues to identify strategic growth areas that align with the evolving challenges of respiratory medicine. Expanding the clinical utility of machine learning-based diagnostic platforms, validating novel biomarkers in diverse patient populations, and enhancing global collaborative networks remain key objectives. Moreover, strengthening translational pathways that connect molecular diagnostics to frontline patient care is an ongoing priority, ensuring that innovations in the laboratory translate into improved clinical outcomes. Looking ahead, Professor Su’s future research aims to deepen the mechanistic understanding of host-pathogen interactions in fungal and viral co-infections, refine AI-driven diagnostic algorithms for pulmonary infections, and integrate multi-omics data into clinical decision-making frameworks. His vision is to establish an internationally recognized precision-medicine model for diagnosing and managing severe respiratory infections, ultimately contributing to reduced mortality, optimized therapeutic strategies, and global health resilience in the era of emerging respiratory pathogens. He has 2677 citations from 128 documents with an h-index of 28.

Profiles: Scopus | ORCID

Publications

1. Diagnostic and prognostic roles of interferon-λ1 and interferon-λ3 in bronchoalveolar lavage fluid and plasma in non-neutropenic patients with invasive pulmonary aspergillosis. (2025). Microbiology Spectrum.

2. Rapid and accurate diagnosis of severe pneumonia: Similarities and differences between severe community-acquired pneumonia and hospital-acquired pneumonia/ventilator-associated pneumonia. (2025). Chinese Journal of Tuberculosis and Respiratory Diseases.

3. Development and validation of a machine learning-based diagnostic model for identifying nonneutropenic invasive pulmonary aspergillosis in suspected patients: A multicenter cohort study. (2025). Microbiology Spectrum.

4. Expert consensus on cancer treatment-related lung injury. (2025). Journal of Thoracic Disease.

5. Pentraxin-3 as a novel prognostic biomarker in non-neutropenic invasive pulmonary aspergillosis patients. (2025). Microbiology Spectrum.

Goran Augustin | Abdominal infections | Best Researcher Award

Published on by Infectious

Dr. Goran Augustin | Abdominal infections | Best Researcher Award 

MD, PhD | University Hospital Centre Zagreb | Croatia

Dr. Goran Augustin, MD, PhD, is a distinguished abdominal surgeon and academic professional whose work integrates advanced surgical practice with translational medical research. His expertise encompasses complex abdominal and gastrointestinal procedures, minimally invasive surgery, and clinical innovations aimed at improving patient outcomes and surgical precision. Throughout his career, he has contributed significantly to scientific literature through a robust portfolio of publications in reputable international journals, reflecting his dedication to evidence-based surgical advancement and academic excellence. His research collaborations with leading national and global institutions have fostered interdisciplinary approaches to surgical science, combining clinical insight with technological innovation and biomedical research. As an advocate for global health and surgical education, Dr. Rakau has actively participated in initiatives aimed at improving healthcare accessibility, capacity building, and the development of standardized surgical practices across diverse healthcare systems. His scholarly and clinical contributions have had a notable influence on both academic and medical communities, inspiring advancements in surgical methodologies, postoperative care, and patient safety. Through his leadership in clinical research, mentorship of emerging surgeons, and unwavering commitment to enhancing the quality of surgical care worldwide, Dr. Patrick Rakau continues to exemplify excellence in modern abdominal surgery and medical scholarship. He has 6061 citations from 179 documents with an h-index of 36.

Profiles: Google Scholar | Scopus | ORCID

Publications

1. Age Is Not So Important for Risk Stratification in Early Cholecystectomy for Acute Calculous Cholecystitis: A Post-Hoc Analysis of the SPRiMACC Study Database. (2025). Medicina (Lithuania).

2. Anticoagulation management and outcomes in critically ill patients with acute mesenteric ischemia: An international study. (2025). Intensive Care Medicine.

3. Protective ileostomy creation after anterior resection of the rectum (PICARR): A decision-making exploring international survey. (2025). Updates in Surgery.

4. A Survey on the Management of Patients with Severe Traumatic Brain Injury During Pregnancy: The MAMA Study. (2025). Neurocritical Care.

5. Phase angle as a prognostic biomarker in metastatic colorectal cancer: A prospective trial. (2025). World Journal of Experimental Medicine.

Wafa Tombari | Vaccines | Best Researcher Award

Published on by Infectious

Assist. Prof. Dr. Wafa Tombari | Vaccines | Best Researcher Award

Assistant Professor | University Hospital of Sahloul | Tunisia

Dr. Wafa Tombari, Ph.D., is an accomplished Assistant Professor and Research Scientist at the University Hospital of Sahloul, Sousse, specializing in infectious diseases with a focus on virology, vaccine development, and antimicrobial resistance. She holds a Doctoral Diploma in Biology from the Faculty of Sciences in Tunisia, a Master of Science in Microbiology, and a Certificate of Complementary Studies in Statistics and Epidemiological Methods from the Faculty of Medicine in Tunisia. With a distinguished academic and research career, Dr. Tombari has served as an Assistant Professor at both the High Institute of Medical Technologies and the University Hospital of Sahloul, where she has successfully led and collaborated on numerous national and international research projects. Her research integrates molecular biology, bioinformatics, and immunoinformatics to develop computational approaches for vaccine design, antiviral therapeutics, and the study of bacterial resistance mechanisms. She has authored several peer-reviewed publications in reputable international journals, including studies on mRNA-based vaccines for rabies virus and molecular characterization of antimicrobial resistance in Staphylococcus species, highlighting her contributions to advancing biomedical innovation. Beyond her research, Dr. Tombari plays an active role in student mentorship, curriculum development, and scientific outreach, fostering collaboration and innovation within the academic community. Her expertise extends to reverse vaccinology, molecular cloning, and phylogenetic analysis, reflecting her multidisciplinary approach to infectious disease research. Dr. Tombari’s scholarly achievements and professional dedication exemplify her commitment to advancing global health through science and education. She has achieved 119 citations, published 10 scientific documents, and holds an h-index of 5, reflecting her academic influence and research excellence.

Profiles: Scopus | Google Scholar

Featured Publications

1. Tombari, W., Nsiri, J., Larbi, I., Guerin, J. L., & Ghram, A. (2011). Genetic evolution of low pathogenicity H9N2 avian influenza viruses in Tunisia: . Acquisition of new mutations. Virology Journal, 8(1), 467.

2. Tombari, W., Paul, M., Bettaieb, J., Larbi, I., Nsiri, J., Elbehi, I., Gribaa, L., & Ghram, A. (2013). Risk factors and characteristics of low pathogenic avian influenza virus isolated from commercial poultry in Tunisia. PLoS ONE, 8(1), e53524.

3. Boudaoud, A., Mamache, B., Tombari, W., & Ghram, A. (2016). Virus mutations and their impact on vaccination against infectious bursal disease (Gumboro disease). Revue Scientifique et Technique, 35(3), 875–897.

4. Kallel Sellami, M., Zitouni, M., Tombari, W., Ben Ayed, M., Abida, O., Laadhar, L., et al. (2007). Anti-desmoglein-1 antibodies are prevalent in Tunisian patients with hydatidosis and leishmaniasis. British Journal of Dermatology, 156(3), 591–593.

Hu Xueliang | Treatment for Infectious Diseases | Best Researcher Award

Published on by Infectious

Ms. Hu Xueliang | Treatment for Infectious Diseases | Best Researcher Award

Attending doctor | Xinjiang Production and Construction Corps Hospital | China

Dr. Hu Xueliang is a medical researcher affiliated with the Xinjiang Production and Construction Corps Hospital, located in the Xinjiang Uygur Autonomous Region, China. He has developed a multidisciplinary academic foundation built upon rigorous medical education and clinical research training, which fuels his pursuit of excellence in scientific inquiry. His educational background includes advanced studies in clinical medicine and infectious diseases, with specialized exposure to epidemiology, antimicrobial resistance, and translational healthcare practices. Professionally, Dr. Hu has accumulated significant experience working in medical and hospital-based research environments where he has contributed to evidence-based clinical investigations, research collaborations, and the analysis of disease patterns. His research interests span infectious diseases, public health, immunopathology, epidemiological modeling, and antimicrobial stewardship, focusing on the development of innovative strategies for the prevention and control of emerging infectious threats. Dr. Hu demonstrates strong research skills in data collection, statistical evaluation, clinical interpretation, and collaborative project leadership, reflecting a growing engagement in translational research that bridges clinical medicine and public health outcomes. Throughout his developing career, he has earned recognition for his dedication and academic integrity, receiving institutional appreciation and professional commendations for research excellence and medical service. His academic achievements and contributions position him as an emerging scholar within the global medical research community, demonstrating both promise and perseverance. Dr. Hu continues to pursue knowledge dissemination through publications, scientific participation, and health advocacy aimed at improving patient outcomes and public safety. He envisions building a strong research portfolio in infectious disease diagnostics and evidence-based medicine while strengthening global collaboration in health sciences.his current publication metrics indicate 0 Citations  and 1 Document with 0 h-index, reflecting his early-career status and future potential for academic growth.

Profiles : Scopus 

Featured Publications

Hu, X., Guo, X., Sha, J., Dou, Y., Ma, H., Li, H., & Xu, Y. (2025). Analysis of the efficacy of photodynamic therapy in treating cervical lesions and HPV infections and its influencing factors. Photodiagnosis and Photodynamic Therapy, 55, 104786.